Guohua Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Guohua Hu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Chuan Liu
Department of Otorhinolaryngology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
1 shared publication - Guojun Li
Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA
1 shared publication Neil Gross
Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
1 shared publicationShixun Zhong
Department of Otorhinolaryngology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
1 shared publicationYanshi Li
Department of Otorhinolaryngology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
1 shared publication- Yuncheng Li
Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
1 shared publication
Latest Publications
- Open Access
- 19 January 2020
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 24 (4) , 2444-2450
PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells
Radioresistance causes a major problem for improvement of outcomes of patients treated with radiation. Targeting for DNA repair deficient mechanisms is a hallmark of sensitization to resistance. We tested whether Olaparib, a (poly) ADP‐ribose polymerase (PARP) inhibitor, can sensitize the radioresistant FaDu cells to radiotherapy. Radioresistant FaDu cells, called FaDu‐RR cells, were used as the radioresistant hypopharyngeal cancer models. The expression of PARP1 was detected in both FaDu and FaDu‐RR cells. The role of Olaparib in radiosensitization was analysed with several assays including clonogenic cell survival, cell proliferation and cell cycle, and radioresistant xenograft. High expression of PARP1 had a significant effect on enhancing radioresistance in FaDu‐RR cells compared with FaDu cells. After treatment of Olaparib, FaDu‐RR cells showed significantly less and smaller surviving colonies, lower proliferation ability and G2/M arrest than those in the group without treatment. Moreover, Olaparib significantly reduced growth of tumours in FaDu‐RR cell xenografts treated with ionizing radiation. Olaparib can significantly inhibit PARP1 expression and consequently has significant effects on radiosensitization in FaDu‐RR cells. These results indicate that Olaparib may help individualize treatment and improve their outcomes of hypopharyngeal cancer patients treated with radiation.
- 19 January 2020
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 24 (4) , 2444-2450
Open AccessPARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells
Radioresistance causes a major problem for improvement of outcomes of patients treated with radiation. Targeting for DNA repair deficient mechanisms is a hallmark of sensitization to resistance. We tested whether Olaparib, a (poly) ADP‐ribose polymerase (PARP) inhibitor, can sensitize the radioresistant FaDu cells to radiotherapy. Radioresistant FaDu cells, called FaDu‐RR cells, were used as the radioresistant hypopharyngeal cancer models. The expression of PARP1 was detected in both FaDu and FaDu‐RR cells. The role of Olaparib in radiosensitization was analysed with several assays including clonogenic cell survival, cell proliferation and cell cycle, and radioresistant xenograft. High expression of PARP1 had a significant effect on enhancing radioresistance in FaDu‐RR cells compared with FaDu cells. After treatment of Olaparib, FaDu‐RR cells showed significantly less and smaller surviving colonies, lower proliferation ability and G2/M arrest than those in the group without treatment. Moreover, Olaparib significantly reduced growth of tumours in FaDu‐RR cell xenografts treated with ionizing radiation. Olaparib can significantly inhibit PARP1 expression and consequently has significant effects on radiosensitization in FaDu‐RR cells. These results indicate that Olaparib may help individualize treatment and improve their outcomes of hypopharyngeal cancer patients treated with radiation.